Sanofi strengthens its presence in Algeria with €70 million investment

26 September 2013

French drug major Sanofi (Euronext: SAN) revealed today that construction has begun on its new Sidi Abdellah industrial site in Algeria. The groundbreaking ceremony was attended by Sanofi’s chief executive Christopher Viehbacher, and Ministers of the Algerian Republic.

Sanofi and the Algerian Health Minister also signed a letter of intent stating their intention to execute, before the end of the year, an agreement to improve the screening and assessment of cardiovascular risk, diabetes and hyperlipidemia and the evaluation of their common risk factors in the Algerian population together with influenza monitoring. The agreement’s objective will be to promote the awareness, screening and therapeutic education of the Algerian public through a mobile medical clinic and aid in the training of health professionals.

Company’s largest industrial site in Africa

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK